Literature DB >> 27667394

Diosgenin‑induced autophagy and apoptosis in a human prostate cancer cell line.

Chao Nie1, Jie Zhou1, Xiaokang Qin2, Xianming Shi1, Qingqi Zeng1, Jia Liu1, Shihai Yan3, Lei Zhang1.   

Abstract

Diosgenin, a plant steroid compound from Dioscorea nipponica, is an anti-inflammatory, antidiabetic, antitumor, vasodilatory compound, which also reduces blood lipid content and protects against ischemia‑induced neuronal damage. However, a limited number of studies have been performed on the antitumor effect of diosgenin on prostate cancer, the underlying mechanism of which remains to be fully elucidated. In the present study, the effect and underlying mechanism of diosgenin on DU145 human prostate cancer cells was investigated. DU145 cells were cultured in vitro with diosgenin, following which cell proliferation was detected by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay and apoptosis was detected by flow cytometry. In addition, DU145 cells were observed under a transmission electron microscope to confirm autophagy. monodansylcadaverine staining and western blotting indicated the levels of autophagy in DU145 cells. To determine the mechanism underlying the effect of diosgenin on DU145 cells, western blotting was performed to evaluate the involvement of the phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) signaling pathway. To investigate the association between apoptosis and autophagy, DU145 cells were cultured with diosgenin and 3‑methyladenine. Hoechst 33342/propidium iodide double staining was performed to detect apoptosis, and reverse transcription‑quantitative polymerase chain reaction was used to analyze mRNA expression levels of Beclin 1 and B‑cell lymphoma 2. Diosgenin inhibits the proliferation of DU145 cells by activating apoptosis and autophagy, and the mechanism underlying this activation may be associated with the inhibition of the PI3K/Akt/mTOR signaling pathway. In addition, the inhibition of autophagy mediated by diosgenin increases apoptosis and, thus, increases the therapeutic effect. The combination of diosgenin with an autophagy inhibitor may be an effective strategy to increase the antitumor effect of diosgenin.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27667394     DOI: 10.3892/mmr.2016.5750

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  10 in total

1.  Diosgenin inhibits the epithelial-mesenchymal transition initiation in osteosarcoma cells via the p38MAPK signaling pathway.

Authors:  Huaming Huang; Chao Nie; Xiaokang Qin; Jie Zhou; Lei Zhang
Journal:  Oncol Lett       Date:  2019-08-23       Impact factor: 2.967

2.  Diosgenin exhibits tumor suppressive function via down-regulation of EZH2 in pancreatic cancer cells.

Authors:  Wenhao Guo; Yujia Chen; Jinsheng Gao; Kunhong Zhong; Heng Wei; Ke Li; Mei Tang; Xinyu Zhao; Xinyu Liu; Chunlai Nie; Zhu Yuan
Journal:  Cell Cycle       Date:  2019-06-29       Impact factor: 4.534

3.  Combination of the NRF2 Inhibitor and Autophagy Inhibitor Significantly Inhibited Tumorigenicity of Castration-Resistant Prostate Cancer.

Authors:  Yong Zhang; Zhixiang Xin; Baijun Dong; Wei Xue
Journal:  Comput Math Methods Med       Date:  2022-06-20       Impact factor: 2.809

Review 4.  Diosgenin: An Updated Pharmacological Review and Therapeutic Perspectives.

Authors:  Prabhakar Semwal; Sakshi Painuli; Tareq Abu-Izneid; Abdur Rauf; Anshu Sharma; Sevgi Durna Daştan; Manoj Kumar; Mohammed M Alshehri; Yasaman Taheri; Rajib Das; Saikat Mitra; Talha Bin Emran; Javad Sharifi-Rad; Daniela Calina; William C Cho
Journal:  Oxid Med Cell Longev       Date:  2022-05-29       Impact factor: 7.310

5.  Synthesis and potent cytotoxic activity of a novel diosgenin derivative and its phytosomes against lung cancer cells.

Authors:  Liang Xu; Dekang Xu; Ziying Li; Yu Gao; Haijun Chen
Journal:  Beilstein J Nanotechnol       Date:  2019-09-24       Impact factor: 3.649

6.  Diosgenin Loaded Polymeric Nanoparticles with Potential Anticancer Efficacy.

Authors:  Nikita Sharma; Monisha Singhal; R Mankamna Kumari; Nidhi Gupta; Romila Manchanda; Asad Syed; Ali H Bahkali; Surendra Nimesh
Journal:  Biomolecules       Date:  2020-12-16

Review 7.  Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.

Authors:  Milad Ashrafizadeh; Mahshid Deldar Abad Paskeh; Sepideh Mirzaei; Mohammad Hossein Gholami; Ali Zarrabi; Farid Hashemi; Kiavash Hushmandi; Mehrdad Hashemi; Noushin Nabavi; Francesco Crea; Jun Ren; Daniel J Klionsky; Alan Prem Kumar; Yuzhuo Wang
Journal:  J Exp Clin Cancer Res       Date:  2022-03-22

8.  An update on the biological and pharmacological activities of diosgenin.

Authors:  Jae Kwang Kim; Sang Un Park
Journal:  EXCLI J       Date:  2018-01-02       Impact factor: 4.068

Review 9.  Chronic diseases, inflammation, and spices: how are they linked?

Authors:  Ajaikumar B Kunnumakkara; Bethsebie L Sailo; Kishore Banik; Choudhary Harsha; Sahdeo Prasad; Subash Chandra Gupta; Alok Chandra Bharti; Bharat B Aggarwal
Journal:  J Transl Med       Date:  2018-01-25       Impact factor: 5.531

10.  Induction of G2/M Phase Arrest by Diosgenin via Activation of Chk1 Kinase and Cdc25C Regulatory Pathways to Promote Apoptosis in Human Breast Cancer Cells.

Authors:  Wen-Ling Liao; Jing-Yi Lin; Jia-Ching Shieh; Hsiao-Fong Yeh; Yi-Hsien Hsieh; Yu-Chun Cheng; Huei-Jane Lee; Chen-Yang Shen; Chun-Wen Cheng
Journal:  Int J Mol Sci       Date:  2019-12-25       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.